MaxCyte, Inc. splits its revenue into 4 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Product at $18.7 million, 89% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
|---|---|---|---|---|---|---|
| Revenue |
19
|
21
|
22
|
19
|
29
|
22
|
| Product |
16
-26.6%
share 84.2%
|
19
-11.4%
share 89.2%
|
21
+13.4%
share 94.9%
|
19
-32.9%
share 95.4%
|
28
+33.4%
share 96.5%
|
21
share 96.4%
|
| Assay And Other Service Revenue |
2
share 12.3%
|
2
share 9.4%
|
—
|
—
|
—
|
—
|
| Product And Service Other |
—
|
—
|
1
+25.5%
share 5.1%
|
1
-11.9%
share 4.6%
|
1
+29.7%
share 3.5%
|
1
share 3.6%
|
| License |
1
-87.9%
share 3.5%
|
0
-98.2%
share 1.4%
|
16
share 73.9%
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Commercial Physical & Biological Research (SIC 8731)
- Listed as
- MXCT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Rockville, MD
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1287098
- Former names
- MAXCYTE INC (until Sep 18, 2008)
Other Services-Commercial Physical & Biological Research companies
- Iqvia Holdings Inc. IQV
- Incyte Corp INCY
- Medpace Holdings, Inc. MEDP
- Charles River Laboratories International, Inc. CRL
- Icon PLC ICLR
- Absci Corp ABSI
- OmniAb, Inc. OABI
- NRC Health NRC
All 17 Services-Commercial Physical & Biological Research companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.